Mechanistic understanding of in vivo protein corona formation on polymeric nanoparticles and impact on pharmacokinetics
暂无分享,去创建一个
Jong-Min Lim | Morteza Mahmoudi | Omid C Farokhzad | Rohit Karnik | Nicolas Bertrand | Eric A Appel | O. Farokhzad | M. Mahmoudi | R. Karnik | Eric A. Appel | R. Langer | Jong-Min Lim | N. Bertrand | E. M. Lima | Eliana M Lima | Flavio Dormont | Robert Langer | Philippe Grenier | Flavio Dormont | Philippe Grenier | E. Lima
[1] J. Leroux,et al. Pharmacokinetics and biodistribution of N-isopropylacrylamide copolymers for the design of pH-sensitive liposomes. , 2009, Biomaterials.
[2] K. G. Rajeev,et al. Targeted Delivery of RNAi Therapeutics With Endogenous and Exogenous Ligand-Based Mechanisms. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.
[3] C. Macosko,et al. A Strategy for Control of "Random" Copolymerization of Lactide and Glycolide: Application to Synthesis of PEG-b-PLGA Block Polymers Having Narrow Dispersity. , 2011, Macromolecules.
[4] D. Bazile,et al. Stealth Me.PEG-PLA nanoparticles avoid uptake by the mononuclear phagocytes system. , 1995, Journal of pharmaceutical sciences.
[5] S. Lai,et al. Evading immune cell uptake and clearance requires PEG grafting at densities substantially exceeding the minimum for brush conformation. , 2014, Molecular pharmaceutics.
[6] Stefan Tenzer,et al. Quantitative profiling of the protein coronas that form around nanoparticles , 2014, Nature Protocols.
[7] Seyed Moein Moghimi,et al. Complement proteins bind to nanoparticle protein corona and undergo dynamic exchange in vivo. , 2017, Nature nanotechnology.
[8] R. Langer,et al. Nanotechnology for biomaterials engineering: structural characterization of amphiphilic polymeric nanoparticles by 1H NMR spectroscopy. , 1997, Biomaterials.
[9] Sara Linse,et al. Understanding the nanoparticle–protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles , 2007, Proceedings of the National Academy of Sciences.
[10] V. Torchilin,et al. Activity of amphipathic poly(ethylene glycol) 5000 to prolong the circulation time of liposomes depends on the liposome size and is unfavorable for immunoliposome binding to target. , 1991, Biochimica et biophysica acta.
[11] Robert Langer,et al. Immunocompatibility properties of lipid-polymer hybrid nanoparticles with heterogeneous surface functional groups. , 2009, Biomaterials.
[12] H. Soleimanjahi,et al. Accelerated Blood Clearance of PEGylated PLGA Nanoparticles Following Repeated Injections: Effects of Polymer Dose, PEG Coating, and Encapsulated Anticancer Drug , 2012, Pharmaceutical Research.
[13] Chad A Mirkin,et al. The role radius of curvature plays in thiolated oligonucleotide loading on gold nanoparticles. , 2009, ACS nano.
[14] P. Butko,et al. Studies of group B streptococcal infection in mice deficient in complement component C3 or C4 demonstrate an essential role for complement in both innate and acquired immunity. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[15] Ralph Weissleder,et al. Tumour-associated macrophages act as a slow-release reservoir of nano-therapeutic Pt(IV) pro-drug , 2015, Nature Communications.
[16] Yun Yen,et al. First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies , 2013, Investigational New Drugs.
[17] N. Maeda,et al. Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic stem cells. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[18] Giulio Caracciolo,et al. Effect of polyethyleneglycol (PEG) chain length on the bio-nano-interactions between PEGylated lipid nanoparticles and biological fluids: from nanostructure to uptake in cancer cells. , 2014, Nanoscale.
[19] Iseult Lynch,et al. Physical-chemical aspects of protein corona: relevance to in vitro and in vivo biological impacts of nanoparticles. , 2011, Journal of the American Chemical Society.
[20] Si-Shen Feng,et al. Effects of Particle Size and Surface Modification on Cellular Uptake and Biodistribution of Polymeric Nanoparticles for Drug Delivery , 2013, Pharmaceutical Research.
[21] F M Muggia,et al. Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.
[22] Stephen G. Young,et al. A mouse model of human familial hypercholesterolemia: Markedly elevated low density lipoprotein cholesterol levels and severe atherosclerosis on a low-fat chow diet , 1998, Nature Medicine.
[23] Sung Tae Kim,et al. Regulation of Macrophage Recognition through the Interplay of Nanoparticle Surface Functionality and Protein Corona. , 2016, ACS nano.
[24] Stefan Tenzer,et al. Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology. , 2013, Nature nanotechnology.
[25] Warren C W Chan,et al. Mediating tumor targeting efficiency of nanoparticles through design. , 2009, Nano letters.
[26] James E Bear,et al. Nanoparticle clearance is governed by Th1/Th2 immunity and strain background. , 2013, The Journal of clinical investigation.
[27] J. Hrkach. Docetaxel Nanoparticle with a Differentiated Pharmacological Profile Preclinical Development and Clinical Translation of a PSMA-Targeted , 2012 .
[28] S. Young,et al. A mouse model of human familial hypercholesterolemia: Markedly elevated low density lipoprotein cholesterol levels and severe atherosclerosis on a low-fat chow diet , 1998, Nature Medicine.
[29] Helmut Thissen,et al. Effects of cloud-point grafting, chain length, and density of PEG layers on competitive adsorption of ocular proteins. , 2002, Biomaterials.
[30] V. Torchilin,et al. Influence of the steric barrier activity of amphipathic poly(ethyleneglycol) and ganglioside GM1 on the circulation time of liposomes and on the target binding of immunoliposomes in vivo , 1991, FEBS letters.
[31] Katharina Landfester,et al. Protein adsorption is required for stealth effect of poly(ethylene glycol)- and poly(phosphoester)-coated nanocarriers. , 2016, Nature nanotechnology.
[32] S Moein Moghimi,et al. Distinct polymer architecture mediates switching of complement activation pathways at the nanosphere-serum interface: implications for stealth nanoparticle engineering. , 2010, ACS nano.
[33] Robert Langer,et al. Nanoparticles with photoinduced precipitation for the extraction of pollutants from water and soil , 2015, Nature Communications.
[34] Robert Langer,et al. Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel Nanoparticle with a Differentiated Pharmacological Profile , 2012, Science Translational Medicine.
[35] Philip M. Kelly,et al. Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. , 2013, Nature nanotechnology.
[36] Robert Langer,et al. Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman primates , 2014, Proceedings of the National Academy of Sciences.
[37] Lawrence Tamarkin,et al. Phase I and Pharmacokinetic Studies of CYT-6091, a Novel PEGylated Colloidal Gold-rhTNF Nanomedicine , 2010, Clinical Cancer Research.
[38] Fang-Yu Chen,et al. The condensing effect of cholesterol in lipid bilayers. , 2007, Biophysical journal.
[39] H. Ueno,et al. A phase I and pharmacokinetic study of NK105, a paclitaxel-incorporating micellar nanoparticle formulation , 2007, British Journal of Cancer.
[40] D. Hochstrasser,et al. Relative quantification of proteins in human cerebrospinal fluids by MS/MS using 6-plex isobaric tags. , 2008, Analytical chemistry.
[41] Robert Langer,et al. Parallel microfluidic synthesis of size-tunable polymeric nanoparticles using 3D flow focusing towards in vivo study. , 2013, Nanomedicine : nanotechnology, biology, and medicine.
[42] M. Mann,et al. Exponentially Modified Protein Abundance Index (emPAI) for Estimation of Absolute Protein Amount in Proteomics by the Number of Sequenced Peptides per Protein*S , 2005, Molecular & Cellular Proteomics.
[43] H. Kasukawa,et al. Comparative studies of polyethylene glycol-modified liposomes prepared using different PEG-modification methods. , 2012, Biochimica et biophysica acta.
[44] James E Bear,et al. PEGylated PRINT nanoparticles: the impact of PEG density on protein binding, macrophage association, biodistribution, and pharmacokinetics. , 2012, Nano letters.
[45] V. Torchilin,et al. Biodegradable long-circulating polymeric nanospheres. , 1994, Science.
[46] Petra Krystek,et al. Particle size-dependent organ distribution of gold nanoparticles after intravenous administration. , 2008, Biomaterials.
[47] T. Willnow,et al. The low-density lipoprotein receptor gene family: a cellular Swiss army knife? , 2002, Trends in cell biology.
[48] Cui Tang,et al. Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. , 2010, Biomaterials.
[49] V. M. Holers,et al. In Vitro and In Vivo Differences in Murine Third Complement Component (C3) Opsonization and Macrophage/Leukocyte Responses to Antibody-Functionalized Iron Oxide Nanoworms , 2017, Front. Immunol..
[50] Andrew Emili,et al. Nanoparticle size and surface chemistry determine serum protein adsorption and macrophage uptake. , 2012, Journal of the American Chemical Society.
[51] Janos Szebeni,et al. Complement activation-related pseudoallergy: a stress reaction in blood triggered by nanomedicines and biologicals. , 2014, Molecular immunology.
[52] Robert Langer,et al. Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. , 2007, Biomaterials.
[53] R. Hammer,et al. Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. , 1993, The Journal of clinical investigation.
[54] Raimo Hartmann,et al. In vivo integrity of polymer-coated gold nanoparticles. , 2015, Nature nanotechnology.
[55] Ashley M. Laughney,et al. Predicting therapeutic nanomedicine efficacy using a companion magnetic resonance imaging nanoparticle , 2015, Science Translational Medicine.
[56] O. Farokhzad,et al. Targeted nanoparticles containing the proresolving peptide Ac2-26 protect against advanced atherosclerosis in hypercholesterolemic mice , 2015, Science Translational Medicine.
[57] V. M. Holers,et al. Modulatory Role of Surface Coating of Superparamagnetic Iron Oxide Nanoworms in Complement Opsonization and Leukocyte Uptake. , 2015, ACS nano.
[58] Robert Langer,et al. Microfluidic platform for controlled synthesis of polymeric nanoparticles. , 2008, Nano letters.
[59] Kazuo Maruyama,et al. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes , 1990, FEBS letters.
[60] Kenneth A. Dawson,et al. Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts , 2008, Proceedings of the National Academy of Sciences.
[61] H. Lutz,et al. The Role of Complement Activation in Hypersensitivity to Pegylated Liposomal Doxorubicin (Doxil®) , 2000 .
[62] Marco P Monopoli,et al. Biomolecular coronas provide the biological identity of nanosized materials. , 2012, Nature nanotechnology.
[63] J. Leroux,et al. Transmembrane pH-gradient liposomes to treat cardiovascular drug intoxication. , 2010, ACS nano.